ATE264112T1 - Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus - Google Patents

Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus

Info

Publication number
ATE264112T1
ATE264112T1 AT97907134T AT97907134T ATE264112T1 AT E264112 T1 ATE264112 T1 AT E264112T1 AT 97907134 T AT97907134 T AT 97907134T AT 97907134 T AT97907134 T AT 97907134T AT E264112 T1 ATE264112 T1 AT E264112T1
Authority
AT
Austria
Prior art keywords
treatment
diabetes mellitus
autoimmune diseases
dependent diabetes
particularly insulin
Prior art date
Application number
AT97907134T
Other languages
English (en)
Inventor
Jean-Francois Bach
Jean-Marc Gombert
Andre Herbelin
Michel Morre
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Application granted granted Critical
Publication of ATE264112T1 publication Critical patent/ATE264112T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
AT97907134T 1996-02-28 1997-02-26 Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus ATE264112T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9602501A FR2745185B1 (fr) 1996-02-28 1996-02-28 Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
PCT/FR1997/000343 WO1997031648A1 (fr) 1996-02-28 1997-02-26 Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant

Publications (1)

Publication Number Publication Date
ATE264112T1 true ATE264112T1 (de) 2004-04-15

Family

ID=9489676

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97907134T ATE264112T1 (de) 1996-02-28 1997-02-26 Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus

Country Status (13)

Country Link
US (2) US6713053B1 (de)
EP (1) EP0883406B1 (de)
JP (1) JP3138481B2 (de)
AT (1) ATE264112T1 (de)
AU (1) AU1929397A (de)
BR (1) BR9707776A (de)
DE (1) DE69728654T2 (de)
DK (1) DK0883406T3 (de)
ES (1) ES2217396T3 (de)
FR (1) FR2745185B1 (de)
NO (1) NO321569B1 (de)
PT (1) PT883406E (de)
WO (1) WO1997031648A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
TWI596114B (zh) 2010-02-24 2017-08-21 雷那特神經科學股份有限公司 拮抗劑抗-ｉｌ-７受體抗體及方法
WO2013088114A1 (en) 2011-12-12 2013-06-20 Cell Medica Limited Process of expanding t cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
DK2812431T3 (da) 2012-02-09 2019-10-14 Baylor College Medicine Peptidblandinger til generering af multivirale ctl'er med bred specificitet
EP3041494A4 (de) * 2013-09-05 2017-10-18 Sanford-Burnham Medical Research Institute Modulation von gamma delta t-zellen
SG10202112047TA (en) 2015-09-18 2021-12-30 Baylor College Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5474769A (en) * 1991-03-08 1995-12-12 Sterling Winthrop Inc. Treatment of microbial infection by monocyte stimulation with interleukin-7
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant

Also Published As

Publication number Publication date
DE69728654T2 (de) 2005-03-24
BR9707776A (pt) 1999-07-27
DK0883406T3 (da) 2004-08-02
EP0883406B1 (de) 2004-04-14
JP3138481B2 (ja) 2001-02-26
FR2745185A1 (fr) 1997-08-29
NO983917D0 (no) 1998-08-26
WO1997031648A1 (fr) 1997-09-04
JPH11508605A (ja) 1999-07-27
NO983917L (no) 1998-10-28
US20040180037A1 (en) 2004-09-16
AU1929397A (en) 1997-09-16
NO321569B1 (no) 2006-06-06
US6713053B1 (en) 2004-03-30
ES2217396T3 (es) 2004-11-01
FR2745185B1 (fr) 1998-05-15
EP0883406A1 (de) 1998-12-16
PT883406E (pt) 2004-08-31
DE69728654D1 (de) 2004-05-19

Similar Documents

Publication Publication Date Title
Pomahač et al. Tissue engineering of skin
DE68928069D1 (de) Anti-T-Zell Rezeptordeterminanten zur Behandlung von Autoimmunkrankheiten
DE69525151D1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
ES2147720T3 (es) Factor de celulas madre.
DE122007000002I2 (de) Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes.
DE69233029D1 (de) Menschliche mesenchym-stammzellen aus dem mark und monoklonale antikörper spezifisch gegen diese zellen
ATE322902T1 (de) Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten
FI971420A0 (fi) Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
DE69113386T2 (de) Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern.
ATE194497T1 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
ATE550030T1 (de) Neue verwendung von antisekretorischem faktor
ATE264112T1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
EP2357223A3 (de) Humane Stammzellen und Verfahren zur Verwendung
ATE174629T1 (de) Herstellung von proteinen mittels protein 7b2
DE69633393D1 (de) Mitteln zur behandlung von auto-immun krankheiten
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
FI971427A0 (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
DE69333962D1 (de) Modifizierte zellen auf der basis des betain-katabolismus, herstellung und verwendung insbesondere zur herstellung von metaboliten oder enzymen
ATE103989T1 (de) Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung.
IL99940A0 (en) Beta-galactoside binding proteins,methods for the production thereof,and pharmaceutical compositions containing the same
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69731284D1 (de) Verwendung Von Coxiella Bakterien zur Behandlung von Autoimmunkrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0883406

Country of ref document: EP